| Form of release | Blister (25 tablets), Pack (100 tablets) |
|---|---|
| International Name | Ligandrol (LGD-4033) |
| Chemical Name | 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonитрил |
| Type of Drug Combination | SARM (selective androgen receptor modulator) |
| Molecular Formula | C14H12F6N2O |
| Molecular Weight | 338.25 g/mol |
| Halflife | 24–36 hours, 24–36 hours |
| Mechanism of Action | Selectively binds to androgen receptors in muscle and bone tissue, activating protein synthesis and muscle fiber growth without significantly affecting the prostate. |
| Anabolic Activity | High |
| Androgenic Activity | Very low |
| Main Effects | Increased muscle mass, strength, and muscle density; improved recovery; increased bone density; minimal water retention |
| Side Effects | Slight suppression of testosterone, possible decrease in libido after the course, rare cases of fatigue or headache |
| thenecessityofpct | Recommended for long-term courses (>6 weeks), Recommended for long-term courses (>6 weeks) |
| Recommended Dosage | 5–15 mg per day |
| Course Duration | 6–10 weeks |
| Reception Hours | Once a day, preferably in the morning |
| Impact on Estrogens | No |
| Impact on the Liver | Moderate |
| Storage | In a dry, cool place, protected from light, at a temperature not exceeding 25°C, In a dry, cool place, protected from light, at a temperature not exceeding 25°C |
| Use by Women | Acceptable in doses of 2.5–5 mg per day, but signs of virilization are possible with prolonged use. |
| Detection Period in the body | Up to 3–4 weeks |
